Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Small Cell Lung Carcinoma Antigen (SCLC Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone MOC-52 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IF, ICC |
|---|---|
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgG1, kappa |
| Clone Names | MOC-52 |
| Calculated MW | 145kDa |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
|---|---|
| Precautions | Small Cell Lung Carcinoma Antigen (SCLC Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This MAb reacts with a membrane-associated protein present in normal and malignant neuroendocrine tissues including small cell lung cancer (SCLC). It stains neural and a variable number of endocrine tissues and in the lung it reacts preferentially with SCLC and carcinoids. Its epitope is destroyed during formalin fixation. This antibody was categorized during the First International Workshop on Small Cell Lung Cancer Antigens held in London in April 1987. There are two major types of Lung Carcinoma: non-small cell, which accounts for 80% of all cases; and small cell, which accounts for roughly 20% of all lung cancers reported. The lung continues to be a customary place for cancer migration from tumors elsewhere in the body. Treatment depends on the specific cell type of the cancer, level of progression and status of the individual patient.
References
W.H.O., 1982, 2nd ed. Am J. Clin. Path. 77, 123-136. | De Leij, L., et al., 1984, Eur. J. Canc. Clin. Oncol. 20, 123-128. | Souhami, R.L., et al., 1987, Lancet ii, 325-326. | De Leij, L., et al., 1987, In: Application of Monoclonal antibodies in tumor pathology (Ruiter DJ et al., eds), Dordrecht: Martinus Nijhoff, pp 191-210. | Berendsen, H.H., de Leij, L., Postmus, P.E., Ter Haar, J.G., Poppema, S. and The, T.H. 1988. Detection of small cell lung cancer metastases in bone marrow aspirates using monoclonal antibody directed against neuroendocrine differentiation antigen. J. Clin. Pathol. 41: 273-276
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Shipping Information
